On 20 June 2024, the trading in Cinclus Pharma Holding AB:s shares commenced on Nasdaq Stockholm. The price in the offering was SEK 42 per share, corresponding to a total market value of the company of approximately SEK 1.24 billion.

Cinclus Pharma is a clinical stage pharmaceutical company focused on the development of the drug candidate linaprazan glurate, a proprietary “prodrug” of the molecule linaprazan, originally developed by AstraZeneca. Linaprazan glurate represents a new and innovative mode of action for the treatment of erosive gastroesophageal reflux disease (eGERD) where there is currently a lack of sufficiently effective treatment options.

Carnegie Investment Bank och Bryan Garnier & Co acted as Joint Global Coordinators and Joint Bookrunners while ABG Sundal Collier acted as Joint Bookrunner. Baker McKenzie acted as legal advisor to the banks with a Capital Markets team consisting of Henric Roth, Joakim Falkner, Per Blom, Sophie Gidlund and Oscar Bang in Stockholm, Adam Farlow in London as well as Els Janssens in Brussels.
Explore Our Newsroom